株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

自律神経失調症:世界の治験動向

Dysautonomia (Autonomic Dysfunction) Global Clinical Trials Review, H2, 2017

発行 GlobalData 商品コード 348445
出版日 ページ情報 英文 63 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
自律神経失調症:世界の治験動向 Dysautonomia (Autonomic Dysfunction) Global Clinical Trials Review, H2, 2017
出版日: 2017年07月28日 ページ情報: 英文 63 Pages
概要

当レポートでは、自律神経失調症治療薬の治験に関する最新動向について分析しており、主要国における治験件数、治験の段階別進行状況、被験者採用の状況、有望なスポンサー、企業や研究機関における研究の進行状況、有望な薬剤の比較などの情報を提供しています。

当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の主要国における治験件数
    • 欧州の主要国における治験件数
    • 北米の主要国における治験件数

G7諸国での治験件数:自律神経失調症

G7諸国における段階別の治験件数

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:自律神経失調症

E7諸国での治験件数:進捗状況別

段階別の治験件数

  • 進行中の治験:段階別

進捗状況別の治験件数

治験の目標の達成状況

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

自律神経失調症治療薬の治験に携わっている主要企業

有望な薬剤

治験プロファイルの概要

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC4407CTIDB

GlobalData's clinical trial report, "Dysautonomia (Autonomic Dysfunction) Global Clinical Trials Review, H2, 2017" provides an overview of Dysautonomia (Autonomic Dysfunction) clinical trials scenario. This report provides top line data relating to the clinical trials on Dysautonomia (Autonomic Dysfunction). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • GlobalData Clinical Trials Report Coverage 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
  • Top Countries Contributing to Clinical Trials in Europe 12
  • Top Countries Contributing to Clinical Trials in North America 13
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 14
  • Clinical Trials by G7 Countries: Proportion of Dysautonomia (Autonomic Dysfunction) to Other Diseases Clinical Trials 15
  • Clinical Trials by Phase in G7 Countries 17
  • Clinical Trials in G7 Countries by Trial Status 18
  • Clinical Trials by E7 Countries: Proportion of Dysautonomia (Autonomic Dysfunction) to Other Diseases Clinical Trials 20
  • Clinical Trials by Phase 22
  • In Progress Trials by Phase 23
  • Clinical Trials by Trial Status 24
  • Clinical Trials by End Point Status 26
  • Subjects Recruited Over a Period of Time 27
  • Clinical Trials by Sponsor Type 28
  • Prominent Sponsors 29
  • Top Companies Participating in Dysautonomia (Autonomic Dysfunction) Therapeutics Clinical Trials 30
  • Prominent Drugs 31
  • Clinical Trial Profile Snapshots 33

Appendix 61

  • Abbreviations 61
  • Definitions 61
  • Research Methodology 62
  • Secondary Research 62
  • About GlobalData 63
  • Contact Us 63
  • Source 63

List of Tables

List of Tables

  • Dysautonomia (Autonomic Dysfunction) Therapeutics, Global, Clinical Trials by Region, 2017* 7
  • Dysautonomia (Autonomic Dysfunction) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
  • Dysautonomia (Autonomic Dysfunction) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
  • Dysautonomia (Autonomic Dysfunction) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 11
  • Dysautonomia (Autonomic Dysfunction) Therapeutics Clinical Trials, Europe, Top Countries, 2017* 12
  • Dysautonomia (Autonomic Dysfunction) Therapeutics Clinical Trials, North America, Top Countries, 2017* 13
  • Dysautonomia (Autonomic Dysfunction) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 14
  • Proportion of Dysautonomia (Autonomic Dysfunction) to Other Diseases Clinical Trials, G7 Countries (%), 2017* 16
  • Dysautonomia (Autonomic Dysfunction) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
  • Dysautonomia (Autonomic Dysfunction) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 19
  • Proportion of Dysautonomia (Autonomic Dysfunction) to Other Diseases Clinical Trials, E7 Countries (%), 2017* 21
  • Dysautonomia (Autonomic Dysfunction) Therapeutics, Global, Clinical Trials by Phase, 2017* 22
  • Dysautonomia (Autonomic Dysfunction) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 23
  • Dysautonomia (Autonomic Dysfunction) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 25
  • Dysautonomia (Autonomic Dysfunction) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 26
  • Dysautonomia (Autonomic Dysfunction) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 27
  • Dysautonomia (Autonomic Dysfunction) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 28
  • Dysautonomia (Autonomic Dysfunction) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 29
  • Dysautonomia (Autonomic Dysfunction) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 30
  • Dysautonomia (Autonomic Dysfunction) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 32

List of Figures

List of Figures

  • Dysautonomia (Autonomic Dysfunction) Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
  • Dysautonomia (Autonomic Dysfunction) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Dysautonomia (Autonomic Dysfunction) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
  • Dysautonomia (Autonomic Dysfunction) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 11
  • Dysautonomia (Autonomic Dysfunction) Therapeutics Clinical Trials, Europe, Top Countries (%), 2017* 12
  • Dysautonomia (Autonomic Dysfunction) Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 13
  • Proportion of Dysautonomia (Autonomic Dysfunction) to Other Diseases Clinical Trials, G7 Countries (%), 2017* 15
  • Dysautonomia (Autonomic Dysfunction) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
  • Dysautonomia (Autonomic Dysfunction) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
  • Proportion of Dysautonomia (Autonomic Dysfunction) to Other Diseases Clinical Trials, E7 Countries (%), 2017* 20
  • Dysautonomia (Autonomic Dysfunction) Therapeutics, Global, Clinical Trials by Phase (%), 2017* 22
  • Dysautonomia (Autonomic Dysfunction) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 23
  • Dysautonomia (Autonomic Dysfunction) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
  • Dysautonomia (Autonomic Dysfunction) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 26
  • Dysautonomia (Autonomic Dysfunction) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 27
  • Dysautonomia (Autonomic Dysfunction) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 28
  • Dysautonomia (Autonomic Dysfunction) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 29
  • Dysautonomia (Autonomic Dysfunction) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 30
  • Dysautonomia (Autonomic Dysfunction) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 31
  • GlobalData Methodology 62
Back to Top